We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Computer Program Confirms Relationship of cfDNA and Tumor DNA

By LabMedica International staff writers
Posted on 16 Nov 2017
Print article
Image: Circulating tumor DNA (ct or cfDNA) is found in serum and plasma fractions from blood. The mechanism of cfDNA release is unknown, though apoptosis, necrosis, and active secretion from tumor cells have been hypothesized (Photo courtesy of Wikimedia Commons).
Image: Circulating tumor DNA (ct or cfDNA) is found in serum and plasma fractions from blood. The mechanism of cfDNA release is unknown, though apoptosis, necrosis, and active secretion from tumor cells have been hypothesized (Photo courtesy of Wikimedia Commons).
Cancer researchers have developed an accurate, scalable approach for monitoring cell-free tumor DNA from blood samples.

Development of this approach was based on the hypothesis that whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood. However, the genome-wide concordance between cfDNA in blood samples and tumor biopsies was uncertain.

To confirm the relationship between cfDNA in the blood and DNA from cancer cells in tumors, investigators at the Broad Institute of the Massachusetts Institute of Technology and Harvard University (Cambridge, MA, USA) developed ichorCNA, a computer program able to analyze DNA fragments for mutation patterns nearly universal in cancer genomes, and as a result able to identify cancers with both known and unknown mutations. The ichorCNA, software quantified tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations.

The investigators reported in the November 6, 2017, online edition of the journal Nature Communications, that they used ichorCNA to analyze 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients had at least 10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing.

Using whole-exome sequencing, the investigators validated the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients that had more than 10% tumor cfDNA in the serum.

"Our study has demonstrated that we can get a cancer whole exome reliably, from blood; that it reflects the matched tumor biopsy; and that it can be done for a significant fraction of patients with metastatic cancer," said first author Dr. Viktor Adalsteinsson, leader of the blood biopsy team at the Broad Institute. "This validation suggests that we can use blood biopsies for large-scale genomic characterization of disease in patients with metastatic cancer. Our ultimate hope is to use blood biopsies to exhaustively search for and characterize even the smallest remnants of tumors, and, as tumors evolve in more advanced stages of cancer, developing resistance or becoming metastatic, we might access time points that could be pivotal in deciding which therapies are right for that patient."

Related Links:
Broad Institute

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.